Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents

Archives of Ophthalmology

Volumn 117, Issue 5, 1999, Pages 586-591

  Mans, Todd L ^a   Nau, Chérie ^a   Bmbaher, Richard F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; BRIMONIDINE; LATANOPROST; PLACEBO; TIMOLOL MALEATE;

AQUEOUS HUMOR FLOW; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032891301     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.5.586     Document Type: Article

References (35)

1. Greenfield DS, Liebmann JM, Riten R. Brimonidine: a new aj-adrenoceptor agonist for glaucoma treatment. J Glaucoma. 1997:6:250-258.
2. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A1 -year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial: Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852.
3. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104:131-136.
4. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(suppI1):S9-S18.
5. Serie JB, Podos SM, Lee P-Y, Camras CB, Severin CH. Effect of a2-adrenergic agonists on uveoscleral outflow in rabbits [abstract]. Invest Ophthalmol Vis Sei. 1991;32(suppl):867.
6. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
7. Alphagan [package insert]. Irvine, Calif: Allergan; 1998.
8. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humordynamics in human eyes. Ophthalmology. 1995:102:456-461.
9. lopidine [package insert]. Fort Worth, Tex: Alcon Laboratories; 1995.
10. Koskela T, Brubaker RF. Apraclonidine and timolol: combined effects in previously untreated normal subjects. Arch Ophthalmol. 1991;109:804-806.
11. Gharagozloo NZ, Reif SJ, Brubaker RF. Aqueous flow is reduced by the alphaadrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988; 95:1217-1220.
12. Brubaker RF. Measurement of aqueous flow by fluorophotometry. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St Louis, Mo: CV Mosby Co; 1996:447-454.
13. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369-1372.
14. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. Afluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978; 27:134-142.
15. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure: in the normal eye. Arch Ophthalmol. 1978;96:2045-2048.
16. Schadiu R, Maus TL, Nau CB, Brubaker RF. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 1998:116:1441-1444.
17. Gharagozloo NZ, Brubaker RF. Effect of apraclonidine in long-term timolol users. Ophthalmology. 1991:98:1543-1546.
18. Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol. 1995; 113:287-292.
19. Aim A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. BrJOphlhalmol. 1995:79:12-16.
20. Diestelhorst M, and the German Latanoprost Study Group. Comparison of fixed-ratio combinations of latanoprost and timolol: a randomised, double-masked, multicentre study in glaucoma patients with timolol and latanoprost as controls [abstract]. Invest Ophtha/mol Vis Sei. 1997;38(suppl):S280.
21. Khouri AS, Fechtner RD, Willman MR, Zimmerman TJ. Additivity of latanoprost to beta blockers and topical carbonic anhydrase inhibitors [abstract]. Invest Ophthalmol Vis Sei. 1997;38(suppl):S280.
22. Seong GJ, Lee HK, Lee YG, Kirn HK, Hong YJ. Additivity of latanoprost to -blockers in brown eyes [abstract]. Invest Ophthalmol Vis Sei. 1998;39(suppl):S257.
23. Bârâny OH, Linnér E, Lutjen-Drecoll E, Rohen JW. Structural and functional effects of trabeculectomy in cynomolgus monkeys, I: light microscopy. Albrecht von Graefes Arch Klin Exp Ophthalmol. 1972;184:1-28.
24. Brubaker RF. The effect of intraocular pressure on conventional outflow resistance in the enucleated human eye. Invest Ophthalmol. 1975;14:286-292.
25. Lee DA, Topper ZJE, Brubaker RF. Effect of clonidine on aqueous humor flow in normal human eyes. Éxp Eye Res. 1984:38:239-246.
26. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982:93:232-237.
27. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep, toesf Op/tf/ia/mo/Ws ScJ. 1985:26:1315-1319.
28. Wayman L, Larsson L-l, Maus T, Alto A, Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:1368-1371.
29. Maus TL, Larsson L-l, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997:115:45-49.
30. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sei. 1980;19:256-266.
31. Higgins RG, Brubaker RF. Acute effect of epinephrine on aqueous humor formation in the timolol-treated normal eye as measured by fluorophotometry. Invest Ophthalmol Vis Sei. 1980:19:420-423.
32. Nagataki S, Brubaker RF. Early effect of epinephrine on aqueous formation in the normal human eye. Ophthalmology. 1981 ;88:278-282.
33. Nagataki S, Brubaker RF. Effect of pilocarpine on aqueous humor formation in human beings. Arch Ophtha/mol. 1982;100:818-821.
34. Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ. Prostaglandin F2-lisopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol. 1988:105:30-34.
35. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993:111:1351-1358.